Best GLP-1 for High Blood Pressure: Wegovy vs Zepbound (2026 Comparison)

By Weight Loss Provider Guide Editorial Team · Last verified: May 11, 2026

This page is for information only and is not medical advice. Affiliate disclosure: We may earn a commission when you visit a provider through our links. This does not affect our rankings, recommendations, or editorial independence.

The bottom line, before you scroll

The best GLP-1 for high blood pressure is not the same answer for everyone. The right pick depends on your heart history, how high your blood pressure runs, and whether you want a shot or a pill.

• 1

  For the biggest measured drop in blood pressure → Zepbound (tirzepatide). In the SURMOUNT-1 trial, Zepbound lowered systolic blood pressure by an average of 6.8 mmHg at 72 weeks. A 24-hour blood-pressure sub-study showed drops of up to 10.6 mmHg on the 10 mg dose — close to what some prescription BP drugs deliver.

• 2

  For the strongest heart-protection evidence → Wegovy (semaglutide 2.4 mg). Wegovy is the only weight-loss GLP-1 currently FDA-approved to reduce heart attack, stroke, and cardiovascular death in adults who have heart disease plus overweight or obesity. The SELECT trial showed a 20% lower risk of major heart events.

• 3

  For a daily pill instead of a weekly shot → Foundayo (orforglipron). FDA-approved April 1, 2026, it's the first GLP-1 pill you can take any time of day. The Foundayo label reports placebo-adjusted systolic BP drops of 4.2, 3.7, and 4.9 mmHg on the 5.5 mg, 9 mg, and 17.2 mg doses in adults without diabetes.

A GLP-1 is not a blood pressure medication. It's a weight-loss medication that often lowers blood pressure as a side benefit — mostly through the weight you lose. So you keep taking your BP meds. If your readings run lower after sustained weight loss, your prescriber may taper them. In the pooled STEP trials, 17.7% of people on Wegovy tapered or stopped an antihypertensive medication during the study, compared to 9.0% on placebo.

If you want a clinician-guided start on the strongest BP-reduction data (Zepbound) or the new oral option (Foundayo), the most common path on this page is Ro. Ro Body membership starts at $39 for the first month, then $149/month or as low as $74/month with annual prepay. Medication is billed separately.

Quick verdict — who wins for which kind of buyer

The data: every major GLP-1 ranked by blood-pressure evidence

We pulled the systolic blood pressure (SBP) and diastolic blood pressure (DBP) numbers straight from each medication's primary clinical trial or its FDA label. No vibes. No “studies show.” Real numbers, real sources.

What is the best GLP-1 for high blood pressure?

There's a reason this page commits to a real answer instead of waving at “talk to your doctor.” The blood-pressure evidence is solid. Multiple high-quality trials, ambulatory blood-pressure sub-studies, and meta-analyses pooling tens of thousands of patients. Most pages won't tell you the specific numbers because they don't know them or don't want to commit. We will.

That said — and this is the part that builds trust, not breaks it — none of these medications is a blood-pressure drug. They're weight-loss drugs that lower blood pressure because losing weight lowers blood pressure. There's also a smaller effect that doesn't depend on weight loss — sodium release through the kidneys, better blood-vessel function, and lower nervous-system activation. But weight loss is the heavy hitter.

Why does that matter? Because it means:

• The medication with the biggest weight loss usually has the biggest BP drop. That's tirzepatide (Zepbound), which is why it sits at the top for raw BP reduction.
• The medication with the strongest heart-event data is the one with the actual heart-event trial. That's semaglutide (Wegovy), with SELECT.
• A medication that hasn't finished a heart-event trial can't claim heart-event protection — even if its BP drop is bigger. That's where Zepbound currently sits, while Lilly's SURMOUNT-MMO outcomes trial runs.

Until SURMOUNT-MMO reads out, we have to call the picks separately.

Does high blood pressure qualify you for a GLP-1?

So yes — having hypertension generally helps. But “helps” is not “guarantees.” Two things happen separately:

The FDA label question.

Wegovy, Zepbound, and Foundayo are approved for weight management in adults with obesity OR overweight + at least one weight-related comorbidity. Hypertension is on that comorbidity list. So is type 2 diabetes, high cholesterol, sleep apnea, and a few others. A clinician confirms your BMI and your diagnosis, and the label requirement is met.

The insurance question.

Most commercial insurance plans set their own weight-management coverage rules, which often require:

• Documented BMI ≥30, or BMI ≥27 with comorbidity
• Documented prior weight-loss attempts (sometimes 6+ months of lifestyle intervention)
• Prior authorization from the prescriber
• Step therapy through other medications first
• A specific provider type (sometimes endocrinologist or obesity-medicine clinician)

Need a step-by-step on the qualification process? See our guide on how to get a GLP-1 approved for weight loss.

Can GLP-1s replace blood pressure medication?

Three things are true at the same time, and they all matter:

1. 1

   A GLP-1 can lower your BP. Across trials, the numbers run from about 2 to 11 mmHg systolic, depending on the drug, the dose, and how much weight you lose. Real and meaningful.

2. 2

   A GLP-1 is not a hypertension drug. It's not labeled for hypertension, it doesn't work like a diuretic or ACE inhibitor or beta-blocker, and the BP effect is variable. If you stop the GLP-1, the weight (and the BP) often come back.

3. 3

   Some people can taper BP meds on a GLP-1. In the pooled STEP analysis (published in Obesity, 2025), 17.7% of Wegovy users tapered or stopped an antihypertensive medication during the trial vs 9.0% on placebo. 13.7% reached hypertension remission vs 6.2% on placebo. None of them did it on their own — they did it with a clinician monitoring readings and adjusting doses.

Which GLP-1 has the strongest blood-pressure evidence? The deep dive

Zepbound (tirzepatide) — the biggest measured BP drop

Why it leads on BP: Zepbound is the only weight-loss medication that hits two gut hormones at once — GIP and GLP-1. That dual mechanism produces the largest weight loss of any approved GLP-1 to date, and the BP drop tracks the weight loss.

What the trials showed:

• SURMOUNT-1 (2,539 adults with obesity, no diabetes): Average weight loss of 15–20% at the highest dose over 72 weeks. Office systolic BP dropped 6.8 mmHg vs placebo. At week 72, 58.0% of participants on tirzepatide had a normal BP reading, vs 35.2% on placebo.
• SURMOUNT-1 24-hour ambulatory BP sub-study (~600 participants): Average systolic BP dropped 7.4 mmHg (5 mg), 10.6 mmHg (10 mg), 8.0 mmHg (15 mg). Nighttime systolic BP — a stronger predictor of heart-event risk than daytime readings — also dropped significantly.

The SURMOUNT-1 mediation analysis found about 68% of the systolic BP drop and 71% of the diastolic BP drop came from weight loss itself. The remaining ~30% came from non-weight effects — sodium release through the kidneys, improved blood-vessel function, and dampened sympathetic activation.

Wegovy (semaglutide 2.4 mg) — the strongest cardiovascular outcomes evidence

Why it leads on heart protection: Wegovy is the first and only weight-loss medication ever shown in a large clinical trial to prevent heart attacks and strokes in adults who don't have diabetes.

What the SELECT trial showed:

17,604 adults age 45+ with prior cardiovascular disease and overweight or obesity (no diabetes), followed about 3.3 years on average. Compared to placebo, Wegovy 2.4 mg weekly:

• Reduced major adverse cardiovascular events by 20%
• Lowered systolic BP by 3.3 mmHg on average
• In March 2024, FDA approved a new indication: reducing the risk of major adverse cardiovascular events in adults with established CVD + obesity/overweight

Pooled STEP trials (antihypertensive medication): Across STEP 1, 3, and 4, 17.7% of Wegovy users tapered or discontinued an antihypertensive medication during the trial, vs 9.0% on placebo. 13.7% reached “hypertension remission” vs 6.2% on placebo. (Source: pooled STEP analysis in Obesity, 2025.)

Foundayo (orforglipron) — the new oral option, approved April 2026

Why it matters: Foundayo is the first GLP-1 you can take as a daily pill with no timing restrictions. Rybelsus requires an empty stomach and a 30-minute wait. Foundayo doesn't — take it any time, with or without food or water.

What the ATTAIN-1 trial and the Foundayo label show:

3,127 adults with obesity or overweight + at least one comorbidity (hypertension, high cholesterol, sleep apnea, or cardiovascular disease), no diabetes. Followed 72 weeks.

Saxenda (liraglutide 3.0 mg) — older, smaller effect

Daily injection. Older agent. Smaller BP drop (about 2.5–4 mmHg systolic) and smaller weight loss than the once-weekly options. Generally only relevant when Zepbound, Wegovy, and Foundayo aren't accessible.

Compounded semaglutide and compounded tirzepatide — what they are and aren't

Compounded GLP-1s are prepared by licensed compounding pharmacies on a per-patient prescription. They are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. They should not be described as equivalent to or interchangeable with Wegovy, Zepbound, Ozempic, Mounjaro, or any FDA-approved branded medication.

What that means for the blood-pressure evidence on this page: The BP outcomes cited throughout — SELECT, SURMOUNT-1, the STEP pooled analysis, ATTAIN-1 — come from the named FDA-approved products. We do not transfer those trial BP numbers or cardiovascular outcomes claims to compounded programs.

How a GLP-1 actually lowers your blood pressure

The takeaway: a GLP-1 isn't doing one thing for your blood pressure. It's doing five things at once, with weight loss leading the charge. If you don't lose weight on it, you won't get much of a BP drop.

What kind of BP drop should you expect? — The High-BP GLP-1 Action Plan

Illustrative SBP drop ranges by medication and weight loss

Ranges are illustrative, based on group averages in SURMOUNT-1, SELECT, STEP, and ATTAIN-1. Individual results vary. Not medical advice.

Your next-step action plan

Can you take a GLP-1 with your blood pressure medication?

The BP drug classes most people are on

Bring your full list to whoever prescribes your GLP-1:

The Wegovy and Zepbound labels don't flag major classic pharmacokinetic interactions with these classes. What the labels do flag:

• Diuretics + GI side effects = dehydration risk. Nausea, vomiting, or diarrhea can cause volume depletion, which amplifies a diuretic's BP-lowering effect. Acute kidney injury has been reported in patients with severe GI side effects.
• Sulfonylureas + insulin: hypoglycemia risk. If you have type 2 diabetes and take a sulfonylurea or insulin, adding a GLP-1 increases the risk of low blood sugar. Your prescriber may reduce your sulfonylurea or insulin dose.
• Oral medications + slowed gastric emptying. GLP-1s slow how fast your stomach empties, which can affect how quickly oral drugs are absorbed. Most BP meds don't need timing changes, but mention every oral medication.

Foundayo's extra interaction list

Because Foundayo is a small-molecule pill, it carries interaction considerations the injectable GLP-1s don't:

• Drug-metabolizing enzymes. Foundayo can affect CYP3A4 and OATP1B. Some statins, immunosuppressants, and other medications metabolized through these pathways may need monitoring.
• Oral hormonal contraceptives. Foundayo can reduce contraceptive effectiveness. The label advises switching to a non-oral method or adding a barrier method for 30 days after starting Foundayo and for 30 days after each dose increase.
• Oral medications generally. Like all GLP-1s, Foundayo slows gastric emptying, which affects oral drug absorption.

What “additive BP effect” means in plain English

If your BP runs 130/80 on lisinopril and a GLP-1 takes another 5–8 mmHg off your systolic, you may end up at 122–125. For most people that's fine, or even better than goal. For some — older adults, people on three or more BP meds, people who stand up quickly — it can show up as dizziness, especially when standing. The fix isn't to skip the GLP-1. The fix is to monitor at home, watch for the taper signals below, and let your prescriber adjust your BP medication if needed. Don't change your BP medication on your own.

When your BP medication may need to come down — the signal checklist

Bring this list to your prescriber if you're checking any 2 or more:

Best online providers if you have high blood pressure

Provider Hypertension-Fit Matrix

Scored on five factors: FDA-approved access (3 pts), insurance and prior-auth help (2 pts), transparent pricing (2 pts), clinician and support infrastructure (2 pts), and regulatory and compliance standing (1 pt). 10 points total.

Provider-stated vs independently verified — what we actually checked

Pricing on the open web changes constantly. We re-verify monthly. Always check the provider's live page before checkout.

🥇 Ro — our top pick for FDA-approved GLP-1 access with high blood pressure

Why Ro for this page: Ro carries the two medications that lead our rankings — Zepbound (biggest BP drop in trials) and Foundayo (the new oral option). Ro also carries Wegovy pen and Wegovy pill, which matters if your situation calls for the FDA-approved cardiovascular-risk-reduction medication. Ro publishes membership pricing, matches LillyDirect on branded medication pricing where applicable, runs a free GLP-1 Insurance Coverage Checker, and the insurance concierge can submit prior-authorization paperwork. Prior auth typically takes 2–3 weeks.

Pricing:

• Ro Body membership: $39 for the first month, then $149/month — or as low as $74/month with the annual plan paid upfront.
• Medication, billed separately: Foundayo from $149 first month / $199–$299 monthly thereafter. Zepbound KwikPen from $299 first month / $399–$449 monthly thereafter. Wegovy pricing varies — verify at checkout.

🥈 Sesame Care — best for branded self-pay comparison

Why Sesame for this page: If Wegovy is your pick — because you've had a cardiac event or your insurance only covers semaglutide — Sesame is our secondary path. Their marketplace gives you provider choice (you pick the clinician), shows transparent self-pay prices, and offers Costco-member pricing on Wegovy and Ozempic. Public price cards confirm self-pay options for Wegovy pill, Wegovy pen, Zepbound KwikPen, Foundayo, and Ozempic.

Pricing:

• Success by Sesame: as low as $59/month with annual subscription
• Medication examples (self-pay): Wegovy pill from $149/month; Wegovy pen from $199/month for the first two months then $349/month; Foundayo from $149/month; Zepbound KwikPen from $299/month depending on dose

Hims and Hers — mainstream consumer brand experience

Following the March 2026 Novo Nordisk partnership and formulary expansion, Hims (men) and Hers (women) now list Wegovy pill, Wegovy pen, Zepbound vial, Zepbound KwikPen, Foundayo, Ozempic, and Mounjaro. They're not the strongest BP-evidence pick on this page — Ro is. But for someone who specifically wants the familiar consumer brand experience, they're a legitimate option.

Pricing: Membership currently $39 first month, then $149/month ongoing. Medication billed separately. Not available in all 50 states — verify at checkout. Hims and Hers display customer testimonials with the disclosure that some customers were compensated and that individual results vary.

Eden — our pick for the cash-pay path (with clear caveats)

Pricing (verify current at checkout):

• No membership fee.
• Compounded semaglutide: First month as low as $129 on a 3-month plan.
• Compounded tirzepatide: First month at $249.
• FDA-approved branded options listed: Ozempic, Zepbound, Mounjaro at $1,399/month; Wegovy at $1,695/month per Eden's current public page.

SHED — for the needle-averse cash-pay shopper

If your blood pressure is well-controlled, you're paying cash, and you don't want injections, SHED lists compounded GLP-1 liquid drops and lozenges. SHED's own page discloses that compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. These are not the same as FDA-approved Foundayo or Wegovy pill. Same caution applies: not appropriate as a first pick for anyone with established CVD or uncontrolled hypertension.

🚫 Why we're not leading with MEDVi on this page

What real patients say (and what they don't prove)

The quotes below are from public health forums. They reflect individual experiences. They do not prove that any GLP-1 will produce the same result for you, and they are not used here to support medical efficacy claims. Individual results vary, sometimes significantly.

Who shouldn't start with an online-only GLP-1

Use this list. If any of these applies to you, talk to an in-person clinician first.

• Your BP is uncontrolled (consistently ≥160/100 at home) or your readings are changing a lot week to week
• You've had a chest pain, fainting, severe headache, or stroke-like symptom episode in the last 90 days
• You're on 3 or more BP medications, or a diuretic plus a low-sodium diet
• You have moderate or severe kidney disease (eGFR under 45) or recent dehydration that led to an ER visit
• You take insulin or a sulfonylurea (glipizide, glyburide, glimepiride) for diabetes
• You have a history of pancreatitis or gallbladder disease
• You're pregnant, breastfeeding, or planning pregnancy in the next 2 months
• You have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)

What does a GLP-1 actually cost if you have high blood pressure?

Hypertension + insurance reality: A documented hypertension diagnosis often helps establish medical necessity for weight-management coverage, but plan rules vary. Coverage exclusions for weight-loss medications are common in commercial plans and standard in Medicare for weight loss (Medicare does cover Wegovy specifically for CV risk reduction in adults with established CVD + overweight/obesity). The fastest way to know your situation is to run a free coverage check.

What to track after you start a GLP-1 with high blood pressure

Print this or copy it into your notes app. Simple on purpose.

When to message your prescriber early (don't wait for your next visit):

• Multiple readings under 100/60 in a week
• Multiple readings over 160/100 in a week
• New dizziness when standing
• Persistent vomiting or diarrhea for more than 48 hours (dehydration risk)
• Resting heart rate consistently over 100, or more than 20 bpm above your usual
• Chest pain, severe abdominal pain, or new severe headache — call your primary care, not just the GLP-1 provider

What to bring to your in-person doctor:

• Medication name, dose, start date, and the prescribing provider
• The pharmacy filling it
• Your weekly log
• Your weight trend
• Any side effects
• The next planned dose increase

What we actually verified before recommending these providers

What we verified (live):

• Wegovy DailyMed label: indications, warnings, contraindications, MTC/MEN2 boxed warning
• Zepbound DailyMed label: indications, warnings, contraindications, MTC/MEN2 boxed warning
• Foundayo DailyMed label: indications, dosing, Trial 1 SBP/DBP/pulse data, oral contraceptive interaction, CYP3A4/OATP1B interactions, MTC/MEN2 boxed warning
• Foundayo FDA approval announcement (Eli Lilly, April 1, 2026)
• SELECT trial primary publication (NEJM 2023); FDA cardiovascular risk reduction indication for Wegovy (March 2024)
• SURMOUNT-1 primary publication (NEJM 2022); 24-hour ambulatory BP sub-study (Hypertension/AHA 2024)
• Pooled STEP antihypertensive discontinuation analysis (Obesity, 2025)
• Ro, Sesame Care, Hims/Hers, Eden, and SHED pricing pages — verified May 11, 2026
• FDA Warning Letter to MEDVi, LLC (dba MEDVi), reference 721455-02202026, February 20, 2026
• FDA proposed rule, April 30, 2026 — proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list

Bottom line — your decision shortcut

Frequently asked questions

About this page

This page was written and edited by the Weight Loss Provider Guide editorial team — an independent comparison resource for GLP-1 telehealth providers. The clinical claims on this page are sourced to primary trial publications (SELECT in NEJM 2023; SURMOUNT-1 in NEJM 2022; the SURMOUNT-1 ambulatory BP sub-study in Hypertension/AHA 2024; the pooled STEP analysis in Obesity 2025; ATTAIN-1 data via the Foundayo DailyMed label) and to current FDA prescribing information for each medication. Provider pricing, formulary, and policies were verified live on May 11, 2026.

Sources cited on this page:

1. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023; 389:2221–2232. (SELECT)
2. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022; 387:205–216. (SURMOUNT-1)
3. de Lemos JA, et al. Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With BMI ≥27. Hypertension 2024.
4. Kennedy C, et al. Tirzepatide and blood pressure reduction: stratified analyses of SURMOUNT-1. BMJ Heart 2024.
5. Pooled STEP antihypertensive discontinuation analysis. Obesity, 2025.
6. Marso SP, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. NEJM 2016. (LEADER)
7. Sun F, et al. Effect of glucagon-like peptide-1 receptor agonists on blood pressure, heart rate, and hypertension. PubMed 26358202, 2015.
8. Wegovy Prescribing Information, Novo Nordisk, current label, via DailyMed.
9. Zepbound Prescribing Information, Eli Lilly, current label, via DailyMed.
10. Foundayo (orforglipron) Prescribing Information, Eli Lilly, current label, via DailyMed.
11. Eli Lilly. FDA Approves Lilly's Foundayo (orforglipron), April 1, 2026.
12. U.S. Food and Drug Administration. Warning Letter to MEDVi, LLC (dba MEDVi), 721455-02202026, February 20, 2026.
13. U.S. Food and Drug Administration. Proposed rule to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, April 30, 2026.
14. American College of Cardiology. SELECT Trial Summary, 2023.
15. American Heart Association Newsroom. Tirzepatide blood pressure reduction in obesity, 2024.